Cagrilintide
AM833 / Long-acting amylin analog
- Peptide length
- 37 amino acids
Long-acting acylated peptide analog
Open the sources to check how the studies were done and what they can support.
A long-acting amylin analog studied for weight management, both alone and in combination with semaglutide.
- Family
- Amylin analog
- Research target
- Amylin and calcitonin receptor family
- Molecular form
- Long-acting acylated peptide analog
What to know about the research
The monotherapy trial and CagriSema combination trial answer different questions. Combination results cannot be assigned to cagrilintide alone.
Check the exact compound
Cagrilintide is an amylin analog. It should not be classified as a GLP-1 receptor agonist or equated with CagriSema.
What supports this entry?
The reference list is available. A statement-by-statement source check has not been completed for this entry.
These are selected references, not a complete review of the literature. Source checks were assisted by AI and have not received independent expert review.
Research stage, study quality and regulatory status answer different questions. A study card does not establish treatment benefit or approval.
No study details have been extracted for this exact entry yet. This does not mean that no studies exist. Open the references and check the exact material.
How we prepare and correct these entries